It's a long time ago to march into health products alone. The next stop is Chinese herbal pieces

On September 12, Duyiwei (002219 SZ) announced that it would enter the field of health care products by acquiring 100% of the equity of Baishan sanbaotang Biotechnology Co., Ltd (hereinafter referred to as "sanbaotang") Now it seems that the company's move has a long way to go, and the company is likely to enter the field of Chinese herbal medicine in the future, but the company's current capital situation will pose a greater constraint on future acquisitions Du Yiwei said that the company signed the equity transfer agreement with Wang Yuliang, sun Yuhong and Wang Renxiang to transfer 100% equity of sanbaotang with its own capital of 11.8 million yuan According to the data, sanbaotang has a registered capital of 9 million yuan It is a private high-tech enterprise relying on the rich specialty resources of Changbai Mountain, specializing in the production of green food and health products Focusing on the research and development of high-tech nourishing and health products, the company has developed six series of products of Jizhen Sanbao brand, including forest frog series (Jizhen Sanbao brand forest frog oil vitamin E Soft capsule), deer product series, ginseng series, Ganoderma price series, blueberry series and edible fungus series products, etc In 2012, sanbaotang achieved an operating revenue of 4.1186 million yuan and a net profit of 125100 yuan; from January to July 2013, sanbaotang achieved an operating revenue of 4.572 million yuan and a net profit of 643900 yuan Du Yiwei said that the acquisition is an important measure to achieve the strategic layout of the company, marking that the company has officially entered the field of health care products, which will become a new economic growth point of the company, which may have a positive impact on the company's current and future financial situation and operating results, which is conducive to improving the profitability and sustainable development ability of the company and the interests of all shareholders Recently, the company acquired four hospitals to enter the medical field, launched unique toothpaste to enter the daily chemical field, and signed a contract with American company apexigen to enter into the anti-cancer monoclonal antibody drugs, thus officially entering the biomedical field These diversified measures have attracted market attention This time, we will enter the field of health care products and diversify to the next city The reporter of securities market weekly noted that there was a foreshadowing behind these seemingly unrelated diversified behaviors According to a notice issued by the company on April 15, 2013, the board of directors approved relevant proposals to increase the business scope of the company with the project of "Chinese herbal pieces, daily chemical products, health products, health food, biological products and medical investment management" Now it seems that there are many articles in it At present, the company has made achievements in the fields of daily chemicals, biomedicine, medical investment management, and health products, mainly through acquisition; however, there is still a new project "Chinese Herbal Pieces" that has not been moved, and whether the company will be included in this field through acquisition in the future is fascinating The reporter called the Securities Department of the company, and the other side replied, "since the Chinese herbal pieces are within the business scope of the company, they can be done in the future, but it is uncertain what means to do it." In addition, compared with the "big hand" in the previous purchase of the hospital, the purchase of health care products only cost 11.8 million yuan The selection of the subject matter is "stingy" and conservative The lack of funds or important reasons will become a constraint factor for the future purchase of the company According to the financial report, as of the first half of 2013, the monetary capital on the company's account was 274 million yuan, and the short-term loan was 244 million yuan, almost all of which came from the short-term loan; at the end of 2011, the company's short-term loan was only 50 million yuan, after which the company's many major acquisitions consumed its own funds, resulting in the situation that the current capital turnover is almost entirely based on the short-term loan; however, the intervention The investment in the field of Chinese herbal pieces is not cheap In the future, whether the company can make a larger acquisition, continue to promote diversification with great strides, and whether it can fall into the field of Chinese herbal pieces, capital is a major test.